Caplacizumab and immunosuppressive therapy without firstline therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura

Trial Identifier: EFC16521
Sponsor: Sanofi
Start Date: November 2022
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Austria Wien, Austria, 1090
Belgium Yvoir, Belgium, 5530
Canada, Ontario Toronto, Ontario, Canada, M5B 1W8
Czech Republic Brno, Czech Republic, 62500
Czech Republic Hradec Kralove, Czech Republic, 50005
Czech Republic Praha 2, Czech Republic, 128 00
France Bois Guillaume, France, 76230
France LILLE, France, 59037
France Paris, France, 75010
France PARIS, France, 75012
Germany Berlin, Germany, 10117
Germany Essen, Germany, 45122
Germany Frankfurt am Main, Germany, 60590
Germany Hannover, Germany, 30625
Germany Köln, Germany, 50937
Germany Leipzig, Germany, 04103
Italy, Campania Avellino, Campania, Italy, 83100
Italy, Genova Genova, Italy, 16132
Italy, Lombardia Milano, Lombardia, Italy, 20122
Italy, Verona Verona, Italy, 37134
Italy, Vicenza Vicenza, Italy, 36100
Japan, Okayama Kurashiki-shi, Okayama, Japan, 710-8602
Japan, Saitama Iruma-gun, Saitama, Japan, 350-0495
Netherlands Amersfoort, Netherlands, 3818 TZ
Spain, Madrid, Comunidad de Madrid / Madrid, Madrid, Comunidad de, Spain, 28007
United Kingdom Liverpool, United Kingdom, L7 8XP
United Kingdom, London, City of London, London, City of, United Kingdom, NW1 2PG
United States, Alabama Birmingham, Alabama, United States, 35233
United States, Maryland Baltimore, Maryland, United States, 21287
United States, North Carolina Durham, North Carolina, United States, 27710-4000
United States, Ohio Columbus, Ohio, United States, 43210
United States, Utah Salt Lake City, Utah, United States, 84106